Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Evaxion Biotech A/S Sponsored ADR (EVAX : NSDQ)
 
 • Company Description   
Evaxion Biotech A/S is a clinical-stage biotechnology company. It involved in the development of AI-driven immunotherapies for patients with cancer and infectious diseases. Evaxion Biotech A/S is based in COPENHAGEN, Denmark.

Number of Employees: 61

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.86 Daily Weekly Monthly
20 Day Moving Average: 1,147,481 shares
Shares Outstanding: 23.20 (millions)
Market Capitalization: $43.16 (millions)
Beta: -0.12
52 Week High: $10.00
52 Week Low: $1.51
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -36.95% -28.99%
12 Week -35.64% -29.25%
Year To Date -57.92% -49.41%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Dr. Neergaards Vej 5F
-
Hoersholm,G7 2970
DNK
ph: 45-5353-1850
fax: -
evax-investor@evaxion-biotech.com http://www.evaxion-biotech.com
 
 • General Corporate Information   
Officers
Lars Staal Wegner - Chief Executive Officer
Marianne Sogaard - Chairman of the Board of Directors
Jesper Nyegaard Nissen - Chief Operating Officer
Niels Iversen Moller - Chief Financial Officer
Lars Holtug - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 29970R105
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 23.20
Most Recent Split Date: (:1)
Beta: -0.12
Market Capitalization: $43.16 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.27 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.64
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -8.70%
vs. Previous Quarter: 35.90%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -107.83
12/31/21 - -99.40
09/30/21 - -111.47
ROA
03/31/22 - -78.88
12/31/21 - -77.35
09/30/21 - -82.84
Current Ratio
03/31/22 - 7.55
12/31/21 - 8.03
09/30/21 - 4.16
Quick Ratio
03/31/22 - 7.55
12/31/21 - 8.03
09/30/21 - 4.16
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 1.14
12/31/21 - 1.43
09/30/21 - 0.87
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.37
12/31/21 - 0.10
09/30/21 - 0.20
Debt-to-Capital
03/31/22 - 27.19
12/31/21 - 9.11
09/30/21 - 16.90
 

Powered by Zacks Investment Research ©